Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Research & Development data on record, last reported at $89.2 million in Q4 2025.

  • For Q4 2025, Research & Development rose 23.97% year-over-year to $89.2 million; the TTM value through Dec 2025 reached $316.6 million, up 32.88%, while the annual FY2025 figure was $338.9 million, 42.26% up from the prior year.
  • Research & Development reached $89.2 million in Q4 2025 per VRDN's latest filing, up from $86.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $89.2 million in Q4 2025 and bottomed at $8.1 million in Q3 2021.
  • Average Research & Development over 5 years is $40.6 million, with a median of $38.9 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 227.55% in 2021, then fell 19.31% in 2024.
  • A 5-year view of Research & Development shows it stood at $22.4 million in 2021, then skyrocketed by 75.57% to $39.3 million in 2022, then dropped by 1.93% to $38.6 million in 2023, then surged by 86.63% to $72.0 million in 2024, then grew by 23.97% to $89.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $89.2 million in Q4 2025, $86.3 million in Q3 2025, and $72.0 million in Q4 2024.